Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins
Hanadi M. Baeissa, Tahani Bakhsh, Afnan Mohammed Shakoori, Ghadir Sindi, Randa Mohammed Zaki, Mohammad Azhar Kamal, Hadeel A. Alsufyani, Alaa Hamed Habib, Arwa Ishaq A. Khayyat, Misbahuddin Rafeeq, Deeba Shamim Jairajpuri
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLung Cancer Treatments and Mutations · Cancer-related Molecular Pathways · Lung Cancer Research Studies
The Funding statement for this article is incorrect. The correct Funding statement is as follows: This study is supported by Prince Sattam bin Abdulaziz University, project number PSAU/2024/R/1445
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Baeissa HM, Bakhsh T, Shakoori AM, Sindi G, Zaki RM, Kamal MA, et al. Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK 2, transferase, oxidoreductase and signalling proteins. P Lo S One. 2025;20(10):e 0334013. doi: 10.1371/journal.pone.0334013 41066396 PMC 12510531 · doi ↗ · pubmed ↗